FR001400N1P4 - Common Stock
PHARNEXT SA
EPA:ALPHA (8/26/2024, 7:00:00 PM)
0.0002
+0 (+100%)
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
PHARNEXT SA
14 rue de la Republique
Suresnes ILE-DE-FRANCE
P: 33141092230
Employees: 0
Website: https://www.pharnext.com/fr/
Find more stocks on Euronext Paris - Matif
Find more stocks on the EuroNext
Find more stocks on the European
Find competitors from the same sector on the EuroNext
Find competitors from the same industry on the EuroNext
Find stocks with similar TA and Setup ratings on the EuroNext
Find stocks with similar Fundamental rating on the EuroNext
Find the competitors with the best technical ratings on the EuroNext
Find the competitors with the best technical and setup ratings on the EuroNext
Find the competitors with the best fundamentals on the EuroNext
Find the competitors with the best valuation on the EuroNext
Find the competitors with the best dividend on the EuroNext
Find the competitors with the best analyst ratings on the EuroNext